$1.42
0[0.00%]
Last update: 7:00AM Get Real Time Here
Cue Biopharma
(NASDAQ:CUE)Cue Biopharma Stock (NASDAQ:CUE), Analyst Ratings, Price Targets, Predictions
Cue Biopharma Inc has a consensus price target of $11.86, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from Stifel, Oppenheimer, and Piper Sandler on April 9, 2024, April 9, 2024, and April 3, 2024. With an average price target of $8.67 between Stifel, Oppenheimer, and Piper Sandler, there's an implied 510.33% upside for Cue Biopharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Oppenheimer
Piper Sandler
Jefferies
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cue Biopharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/09/2024 | CUE | Buy Now | Cue Biopharma | $1.42 | 463.38% | Stifel | Stephen Willey | $8 → $8 | Maintains | Buy | Get Alert |
| 04/09/2024 | CUE | Buy Now | Cue Biopharma | $1.42 | 604.23% | Oppenheimer | Leland Gershell | $10 → $10 | Maintains | Outperform | Get Alert |
| 04/03/2024 | CUE | Buy Now | Cue Biopharma | $1.42 | 463.38% | Piper Sandler | Edward Tenthoff | $8 → $8 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2024 | CUE | Buy Now | Cue Biopharma | $1.42 | 322.54% | Jefferies | Maury Raycroft | → $6 | Initiates | → Buy | Get Alert |
| 11/06/2023 | CUE | Buy Now | Cue Biopharma | $1.42 | 463.38% | Piper Sandler | Edward Tenthoff | $7 → $8 | Maintains | Overweight | Get Alert |
| 06/26/2023 | CUE | Buy Now | Cue Biopharma | $1.42 | 604.23% | Oppenheimer | Mark Breidenbach | → $10 | Assumes | Outperform → Outperform | Get Alert |
| 06/15/2023 | CUE | Buy Now | Cue Biopharma | $1.42 | 463.38% | Stifel | Stephen Willey | → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | CUE | Buy Now | Cue Biopharma | $1.42 | 956.34% | JMP Securities | Reni Benjamin | → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 03/22/2023 | CUE | Buy Now | Cue Biopharma | $1.42 | 463.38% | Stifel | Stephen Willey | $9 → $8 | Maintains | Buy | Get Alert |
| 03/22/2023 | CUE | Buy Now | Cue Biopharma | $1.42 | 604.23% | Oppenheimer | Mark Breidenbach | → $10 | Reiterates | → Outperform | Get Alert |
| 11/21/2022 | CUE | Buy Now | Cue Biopharma | $1.42 | 392.96% | Piper Sandler | Edward Tenthoff | → $7 | Initiates | → Overweight | Get Alert |
| 08/24/2022 | CUE | Buy Now | Cue Biopharma | $1.42 | 604.23% | Oppenheimer | Mark Breidenbach | $26 → $10 | Maintains | Outperform | Get Alert |
| 03/21/2022 | CUE | Buy Now | Cue Biopharma | $1.42 | 1730.99% | Oppenheimer | Mark Breidenbach | $32 → $26 | Maintains | Outperform | Get Alert |
| 03/18/2022 | CUE | Buy Now | Cue Biopharma | $1.42 | 1730.99% | Craig-Hallum | Robin Garner | $28 → $26 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cue Biopharma (CUE)?
The latest price target for Cue Biopharma (NASDAQ: CUE) was reported by Stifel on April 9, 2024. The analyst firm set a price target for $8.00 expecting CUE to rise to within 12 months (a possible 463.38% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cue Biopharma (CUE)?
The latest analyst rating for Cue Biopharma (NASDAQ: CUE) was provided by Stifel, and Cue Biopharma maintained their buy rating.
When was the last upgrade for Cue Biopharma (CUE)?
There is no last upgrade for Cue Biopharma.
When was the last downgrade for Cue Biopharma (CUE)?
There is no last downgrade for Cue Biopharma.
When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.
Is the Analyst Rating Cue Biopharma (CUE) correct?
While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a maintained with a price target of $8.00 to $8.00. The current price Cue Biopharma (CUE) is trading at is $1.42, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.